



THE UNITED STATES PATENT AND TRADEMARK OFFICE

PATENT

3/23/98  
Amidra

In re Application of:

TSUKASA MATSUMOTO

Serial No.: 08/803,458

Filed: February 20, 1997

For: METHOD FOR FRACTIONING  
RED BLOOD CELLS AND ANTI-  
BACTERIAL MATERIALS OR  
BACTERIAL PROLIFERATION  
INHIBITORS PRODUCED THEREBY

)  
)  
Group Art Unit: 1651  
)  
Examiner: S. Saucier  
)  
Atty. Dkt. No.: 6208.570  
)  
)  
)  
)  
)

Honorable Commissioner of Patents  
and Trademarks  
Washington, D.C. 20231

RECEIVED

MAR 20 1998

MAILING ROOM  
U.S. PATENT & TRADEMARK OFFICE

AMENDMENT

Dear Sir:

Responsive to the Office Action of August 25, 1997, please amend the above-identified patent application as follows:

**IN THE CLAIMS:**

Please rewrite Claim 1 as follows:

*A1 cont'd*  
1. (Once Amended) Method for fractionating red blood cells of human blood into three fraction, comprising the following steps[;]:

(a) mixing a human blood sample with dextran aqueous solution and maintaining said mixture stationarily for [60 to 75 minutes so as] a period sufficient to fractionate [this] the blood sample into [three layers, the] upper, intermediate, and lower layers;

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.



# TRANSMITTAL FORM

(To be used for all correspondence after initial filing)

Total Number of Pages in This Submission

Application Number	08/803,458
Filing Date	February 20, 1997
First Named Inventor	Tsukasa Matsumoto
Group Art Unit	1651
Examiner Name	S. Saucier
Total Number of Pages in This Submission	6208.570

## ENCLOSURES (check all that apply)

<input checked="" type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Assignment Papers (for an Application)	<input type="checkbox"/> After Allowance Communication to Group
<input checked="" type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input checked="" type="checkbox"/> Amendment / Response	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition Checklist and Accompanying Petition	<input type="checkbox"/> Proprietary Information
<input checked="" type="checkbox"/> Extension of Time Request	<input type="checkbox"/> To Convert a Provisional Application	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input type="checkbox"/> Additional Enclosure(s) (please identify below):
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Terminal Disclaimer	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> Remarks	
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application		
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		

RECEIVED

MAR 20 1998

MATRIX CUSTOMER  
SERVICE CENTER

## SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	Joseph W. Berenato, III, Reg. No. 30,546 Myers, Liniak & Berenato
Signature	
Date	

## CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on this date: 

Typed or printed name	Joseph W. Berenato, III
Signature	
Date	2/24/98

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.